- Home
- SHMD vs XFOR Comparison
SHMD vs XFOR Comparison
Compare SHMD & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHMD
- XFOR
- Stock Information
- Founded
- SHMD 1864
- XFOR 2014
- Country
- SHMD Germany
- XFOR United States
- Employees
- SHMD N/A
- XFOR N/A
- Industry
- SHMD
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SHMD
- XFOR Health Care
- Exchange
- SHMD Nasdaq
- XFOR Nasdaq
- Market Cap
- SHMD 102.1M
- XFOR 84.3M
- IPO Year
- SHMD N/A
- XFOR N/A
- Fundamental
- Price
- SHMD $2.20
- XFOR $2.99
- Analyst Decision
- SHMD
- XFOR Strong Buy
- Analyst Count
- SHMD 0
- XFOR 3
- Target Price
- SHMD N/A
- XFOR $34.17
- AVG Volume (30 Days)
- SHMD 28.9K
- XFOR 1.6M
- Earning Date
- SHMD 01-01-0001
- XFOR 11-12-2025
- Dividend Yield
- SHMD N/A
- XFOR N/A
- EPS Growth
- SHMD N/A
- XFOR N/A
- EPS
- SHMD N/A
- XFOR N/A
- Revenue
- SHMD $85,165,542.00
- XFOR $32,774,000.00
- Revenue This Year
- SHMD N/A
- XFOR $1,313.84
- Revenue Next Year
- SHMD N/A
- XFOR N/A
- P/E Ratio
- SHMD N/A
- XFOR N/A
- Revenue Growth
- SHMD N/A
- XFOR 5721.31
- 52 Week Low
- SHMD $1.86
- XFOR $1.35
- 52 Week High
- SHMD $4.40
- XFOR $26.83
- Technical
- Relative Strength Index (RSI)
- SHMD 35.96
- XFOR 47.72
- Support Level
- SHMD $2.07
- XFOR $3.08
- Resistance Level
- SHMD $2.48
- XFOR $3.79
- Average True Range (ATR)
- SHMD 0.21
- XFOR 0.45
- MACD
- SHMD -0.03
- XFOR -0.12
- Stochastic Oscillator
- SHMD 22.67
- XFOR 2.13
About SHMD SCHMID Group N.V. Class A Ordinary Shares
Schmid Group NV is a global supplier of equipment, software and services for various industries such as printed circuit board (PCB), substrate manufacturing, photovoltaics, and glass and energy storage with a focus on the highest end of this market in terms of technology and performance. It focuses on a modular product portfolio of machinery to use in the manufacturing of high-end PCB equipment and semiconductor packaging devices which includes common flexible circuit fabrication techniques such as subtractive, semi-additive processes (SAP) and modified semi-additive processes (mSAP).
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.